Company intelligence / Profile preview

TotipotentSC

Los Angeles, California, United States

Ownership: Private
Development stage: Other

Overview

TotipotentRx developed eight autologous cell therapies in clinical development for high unmet needs, focusing on point-of-care solutions. Its merger yielded a broader platform and expanded clinical trial capabilities but the original company was subsumed into Cesca Therapeutics post-2013.

Therapeutic areas: RheumatologyCardiovascularOther
Modalities: Cell therapyAutologous cell therapyStem cell therapy
Industry: Biotech

Partnerships

Fortis Healthcare (exclusive provider of cell-based products/services)

Beyond the preview

Go deeper on TotipotentSC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TotipotentSC.

Explore the full profile